Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis...
- Day's Range
- 9.060 - 9.260
- 52 wk Range
- 7.160 - 10.370
- Prev. Close
- Average Vol.(3m)
- 1-Year Change
- Market Cap
- P/E Ratio
- Shares Outstanding
- Dividend (Yield)
- 0.149 (1.63%)
- Next Earnings Date
- Nov 09, 2023
An analyst from RBC Capital maintained Almirall (BME: ALM) at 'outperform' with a price target of EUR12.50. Prior to this rating, Almirall had 7 buy ratings, 5 hold ratings, and 0 sell...
An analyst from Credit Suisse maintained Almirall (BME: ALM) at 'neutral' with a price target of EUR10.00. Prior to this rating, Almirall had 6 buy ratings, 6 hold ratings, and 0 sell...
An analyst from Credit Suisse maintained Almirall (BME: ALM) to 'neutral' and a price target of EUR10.00. Prior to this rating, Almirall had 5 buy ratings, 7 hold ratings, and 0 sell...
Nov 14 (Reuters) - Spanish pharma company Almirall ALM.MC said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months...
LONDON, July 10 (Reuters) - European stocks edged higher on Monday, with banks and utilities the strongest sectors, as mergers and acquisitions rumbled on with some broker notes also...
March 24 (Reuters) - Almirall SA ALM.MC : * The company and Sun Pharma (NS:SUN) announce validation of regulatory filing for Tildrakizumab, an antibody designed for treatment of...
By Arno Schuetze, Pamela Barbaglia and Ludwig Burger FRANKFURT, Oct 13 (Reuters) - Bayer BAYGn.DE has short-listed India's Lupin LUPN.NS and investor BC Partners as prospective buyers of...
July 27 (Reuters) - Almirall SA ALM.MC : * Says enters into a license agreement with Sun Pharma Industries SUN.NS for tildrakizumab in Europe for psoriasis * Says to pay Sun Pharma an...
(Adds futures prices, company news) LONDON, Dec 1 (Reuters) - European shares headed for a stronger start on the first trading day of the month, tracking sharp gains in Asian equities, with...
* Paying Actavis initial $600 mln for N.American lung drugs* Deal builds on last year's purchase of Almirall drugs* 2015 core EPS seen growing by low single-digit percent* Q4 sales...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.